{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:41:40Z","timestamp":1789429300614,"version":"build-2803163510"},"reference-count":35,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Emerging Microbes &amp; Infections"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/emi.2016.116","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T08:21:30Z","timestamp":1478679690000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Application of a low molecular weight antifungal protein from\n            <i>Penicillium chrysogenum<\/i>\n            (PAF) to treat pulmonary aspergillosis in mice"],"prefix":"10.1080","volume":"5","author":[{"given":"Zolt\u00e1n","family":"Palicz","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4012, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"G\u00e1ll","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4012, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Leiter","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Microbiology, Faculty of Science and Technology, University of Debrecen, Debrecen H-4032, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Koll\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ken\u00e9zy Gyula Hospital, Debrecen H-4031, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ken\u00e9zy Gyula Hospital, Debrecen H-4031, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korn\u00e9l","family":"Miszti-Blasius","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical Faculty, University of Debrecen, Debrecen H-4012, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"P\u00f3csi","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Microbiology, Faculty of Science and Technology, University of Debrecen, Debrecen H-4032, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Csernoch","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4012, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Szentesi","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4012, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"e_1_3_2_1_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1473-3099(10)70218-8","article-title":"Emerging opportunistic yeast infections","volume":"11","author":"Miceli MH","year":"2011","unstructured":"MiceliMH,D\u00edazJA,LeeSA.Emerging opportunistic yeast infections.Lancet Infect Dis2011; 11:142\u2013151.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller MA","year":"2012","unstructured":"PfallerMA.Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.Am J Med2012; 125:S3\u2013S13.","journal-title":"Am J Med"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.riam.2010.10.003","article-title":"What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis","volume":"27","author":"Abad A","year":"2010","unstructured":"AbadA,Fern\u00e1ndez-MolinaJV,BikandiJet al.What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis.Rev Iberoam Micol2010; 27:155\u2013182.","journal-title":"Rev Iberoam Micol"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"843763","DOI":"10.1155\/2011\/843763","article-title":"Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis","volume":"2011","author":"Knutsen AP","year":"2011","unstructured":"KnutsenAP,SlavinRG.Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis.Clin Dev Immunol2011; 2011:843763.","journal-title":"Clin Dev Immunol"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: a clinical review","volume":"20","author":"Kousha M","year":"2011","unstructured":"KoushaM,TadiR,SoubaniAO.Pulmonary aspergillosis: a clinical review.Eur Respir Rev2011; 20:156\u2013174.","journal-title":"Eur Respir Rev"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens J","year":"2004","unstructured":"MaertensJ,RaadI,PetrikkosGet al.Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.Clin Infect Dis2004; 39:1563\u20131571.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh TJ","year":"2008","unstructured":"WalshTJ,AnaissieEJ,DenningDWet al.Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America.Clin Infect Dis2008; 46:327\u2013360.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pupt.2014.06.002","article-title":"Current and future therapies for invasive aspergillosis","volume":"32","author":"Bassetti M","year":"2015","unstructured":"BassettiM,PecoriD,Della SiegaPet al.Current and future therapies for invasive aspergillosis.Pulm Pharmacol Ther2015; 32:155\u2013165.","journal-title":"Pulm Pharmacol Ther"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","first-page":"713687","DOI":"10.1155\/2012\/713687","article-title":"Antifungal resistance and new strategies to control fungal infections","volume":"2012","author":"Vandeputte P","year":"2012","unstructured":"VandeputteP,FerrariS,CosteAT.Antifungal resistance and new strategies to control fungal infections.Int J Microbiol2012; 2012:713687.","journal-title":"Int J Microbiol"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard SJ","year":"2009","unstructured":"HowardSJ,CerarD,AndersonMJet al.Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure.Emerg Infect Dis2009; 15:1068\u20131076.","journal-title":"Emerg Infect Dis"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.37.7.2343-2345.1999","article-title":"In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole","volume":"37","author":"Sutton DA","year":"1999","unstructured":"SuttonDA,SancheSE,RevankarSGet al.In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.J Clin Microbiol1999; 37:2343\u20132345.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00018-007-7364-8","article-title":"The Penicillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies","volume":"65","author":"Marx F","year":"2008","unstructured":"MarxF,BinderU,LeiterEet al.The Penicillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies.Cell Mol Life Sci2008; 65:445\u2013454.","journal-title":"Cell Mol Life Sci"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.fbr.2012.07.002","article-title":"Antifungal proteins: more than antimicrobials?","volume":"26","author":"Heged\u0171s N","year":"2013","unstructured":"Heged\u0171sN,MarxF.Antifungal proteins: more than antimicrobials?Fungal Biol Rev2013; 26:132\u2013145.","journal-title":"Fungal Biol Rev"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jobm.201000321","article-title":"The paf gene product modulates asexual development in Penicillium chrysogenum","volume":"51","author":"Heged\u0171s N","year":"2011","unstructured":"Heged\u0171sN,SiglC,ZadraIet al.The paf gene product modulates asexual development in Penicillium chrysogenum.J Basic Microbiol2011; 51:253\u2013262.","journal-title":"J Basic Microbiol"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/j.1742-4658.2009.07011.x","article-title":"Functional aspects of the solution structure and dynamics of PAF\u2014a highly-stable antifungal protein from Penicillium chrysogenum","volume":"276","author":"Batta G","year":"2009","unstructured":"BattaG,BarnaT,G\u00e1sp\u00e1riZet al.Functional aspects of the solution structure and dynamics of PAF\u2014a highly-stable antifungal protein from Penicillium chrysogenum.FEBS J2009; 276:2875\u20132890.","journal-title":"FEBS J"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00203-003-0578-8","article-title":"Characterization of the Penicillium chrysogenum antifungal protein PAF","volume":"180","author":"Kaiserer L","year":"2003","unstructured":"KaisererL,OberparleiterC,Weiler-GorzRet al.Characterization of the Penicillium chrysogenum antifungal protein PAF.Arch Microbiol2003; 180:204\u2013210.","journal-title":"Arch Microbiol"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10482-008-9263-x","article-title":"In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes","volume":"94","author":"Galg\u00f3czy L","year":"2008","unstructured":"Galg\u00f3czyL,PappT,PocsiIet al.In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes.Antonie Van Leeuwenhoek2008; 94:463\u2013470.","journal-title":"Antonie Van Leeuwenhoek"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/AAC.47.11.3598-3601.2003","article-title":"Active internalization of the Penicillium chrysogenum antifungal protein PAF in sensitive aspergilli","volume":"47","author":"Oberparleiter C","year":"2003","unstructured":"OberparleiterC,KaisererL,HaasHet al.Active internalization of the Penicillium chrysogenum antifungal protein PAF in sensitive aspergilli.Antimicrob Agents Chemother2003; 47:3598\u20133601.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1128\/AAC.49.6.2445-2453.2005","article-title":"Antifungal protein PAF severely affects the integrity of the plasma membrane of Aspergillus nidulans and induces an apoptosis-like phenotype","volume":"49","author":"Leiter E","year":"2005","unstructured":"LeiterE,SzappanosH,OberparleiterCet al.Antifungal protein PAF severely affects the integrity of the plasma membrane of Aspergillus nidulans and induces an apoptosis-like phenotype.Antimicrob Agents Chemother2005; 49:2445\u20132453.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jobm.201100041","article-title":"The small molecular mass antifungal protein of Penicillium chrysogenum\u2014a mechanism of action oriented review","volume":"51","author":"Heged\u0171s N","year":"2011","unstructured":"Heged\u0171sN,Leiter\u00c9,Kov\u00e1csBet al.The small molecular mass antifungal protein of Penicillium chrysogenum\u2014a mechanism of action oriented review.J Basic Microbiol2011; 51:561\u2013571.","journal-title":"J Basic Microbiol"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00210-004-1013-7","article-title":"The Penicillium chrysogenum-derived antifungal peptide shows no toxic effects on mammalian cells in the intended therapeutic concentration","volume":"371","author":"Szappanos H","year":"2005","unstructured":"SzappanosH,SzigetiGP,P\u00e1lBet al.The Penicillium chrysogenum-derived antifungal peptide shows no toxic effects on mammalian cells in the intended therapeutic concentration.Naunyn-Schmied Arch Pharmacol2005; 371:122\u2013132.","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.taap.2013.02.014","article-title":"In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF)","volume":"269","author":"Palicz Z","year":"2013","unstructured":"PaliczZ,JenesA,G\u00e1llTet al.In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF).Toxic Appl Pharmac2013; 269:8\u201316.","journal-title":"Toxic Appl Pharmac"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0378-1119(95)00701-6","article-title":"Cloning, structural organization and regulation of expression of the Penicillium chrysogenum\n                  paf gene encoding an abundantly secreted protein with antifungal activity","volume":"167","author":"Marx F","year":"1995","unstructured":"MarxF,HaasH,ReindlMet al.Cloning, structural organization and regulation of expression of the Penicillium chrysogenumpaf gene encoding an abundantly secreted protein with antifungal activity.Gene1995; 167:167\u2013171.","journal-title":"Gene"},{"key":"e_1_3_2_24_1","unstructured":"Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard Document M38-A.Wayne PA USA: CLSI.2008.Available athttp:\/\/shop.clsi.org\/site\/Sample_pdf\/M38A2_sample.pdf."},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds FC","year":"2003","unstructured":"OddsFC.Synergy, antagonism, and what the chequerboard puts between them.J Antimicrob Chemother2003; 52:1.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/genetics\/52.1.233","article-title":"Wild-type and mutant stocks of Aspergillus nidulans","volume":"52","author":"Barratt RW","year":"1965","unstructured":"BarrattRW,JohnsonGB,OgataWN.Wild-type and mutant stocks of Aspergillus nidulans.Genetics1965; 52:233\u2013246.","journal-title":"Genetics"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2009.09.029","article-title":"Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus","volume":"35","author":"Warn PA","year":"2010","unstructured":"WarnPA,SharpA,MorrisseyGet al.Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.Int J Antimicrob Agents2010; 35:146\u2013151.","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0047-6374(93)90014-I","article-title":"A comparison of methods for estimating mortality parameters from survival data","volume":"66","author":"Wilson DL","year":"1993","unstructured":"WilsonDL.A comparison of methods for estimating mortality parameters from survival data.Mech Ageing Develop1993; 66:269\u2013281.","journal-title":"Mech Ageing Develop"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti D","year":"2014","unstructured":"KoulentiD,Garnacho-MonteromJ,BlotS.Approach to invasive pulmonary aspergillosis in critically ill patients.Curr Opin Infect Dis2014; 27:174\u2013183.","journal-title":"Curr Opin Infect Dis"},{"key":"e_1_3_2_30_1","first-page":"361","article-title":"Liposomal amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections","volume":"69","author":"Moen MD","year":"2009","unstructured":"MoenMD,Lyseng-WilliamsonKA,ScottLJ.Liposomal amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Drugs2009; 69:361\u2013392.","journal-title":"Drugs"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/AAC.48.3.758-764.2004","article-title":"Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories","volume":"48","author":"Najvar LK","year":"2004","unstructured":"NajvarLK,CacciapuotiA,HernandezSet al.Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories.Antimicrob Agents Chemother2004; 48:758\u2013764.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.00659-09","article-title":"Anidulafungin in combination with Amphotericin B against Aspergillus fumigatus","volume":"53","author":"Spreghini E","year":"2009","unstructured":"SpreghiniE,OrlandoF,SantinelliAet al.Anidulafungin in combination with Amphotericin B against Aspergillus fumigatus.Antimicrob Agents Chemother2009; 53:4035\u20134039.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/13693780903208249","article-title":"Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B","volume":"48","author":"Chang T","year":"2010","unstructured":"ChangT,OlsonJA,ProffittRTet al.Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B.Med Mycol2010; 48:430\u2013435.","journal-title":"Med Mycol"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/mmy\/myu070","article-title":"Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice","volume":"53","author":"Olson JA","year":"2015","unstructured":"OlsonJA,SchwartzJA,HahkaDet al.Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.Med Mycol2015; 53:107\u2013118.","journal-title":"Med Mycol"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00365549709011864","article-title":"In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole","volume":"29","author":"Chryssanthou E","year":"1997","unstructured":"ChryssanthouE.In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole.Scand J Infect Dis1997; 29:509\u2013512.","journal-title":"Scand J Infect Dis"}],"container-title":["Emerging Microbes &amp; Infections"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/emi2016116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/emi2016116","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1038\/emi.2016.116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/emi2016116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:30:59Z","timestamp":1695299459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1038\/emi.2016.116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1038\/emi.2016.116"],"URL":"https:\/\/doi.org\/10.1038\/emi.2016.116","relation":{},"ISSN":["2222-1751"],"issn-type":[{"value":"2222-1751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}